Curated news and analysis on clinical trials, drug approvals, and medical research.
Altesa BioSciences closed an oversubscribed $75 million Series B financing led by Forbion with participation from Sanofi to advance vapendavir, a first-in-class oral antiviral targeting rhinovirus infections in COPD patients.
Arvinas announced phase 1 results for ARV-102, a PROTAC degrader that achieved more than 50% LRRK2 degradation in cerebrospinal fluid of Parkinson's patients after 28 days, with no serious adverse events reported.
Insilico Medicine announced a partnership with China Medical System Holdings for AI-powered drug discovery and nominated ISM5059, an NLRP3-targeted drug candidate, for preclinical development following recent FDA IND approval for another AI-created drug.
Maryland lawmakers are advancing legislation to eliminate tax breaks for pharmaceutical company advertising, with 73% of residents supporting the measure. The bill would generate at least $23 million annually for Medicaid and the state health insurance marketplace.
Research into Lynch syndrome is advancing cancer prevention through aspirin therapy, vaccine trials, and a major North American study examining why some patients develop cancer while others remain protected.
Global pharmaceutical R&D deal values surged 49% to $86.7 billion in 2025 as companies concentrate investments in AI-powered drug discovery platforms, with average deal sizes reaching a record $1.16 billion despite fewer total partnerships.
The U.S. FDA has granted Fast Track designation to FluoGuide's FG001 as an intraoperative imaging agent for high-grade glioma surgical resection. The designation follows IND clearance in January and enables accelerated development and regulatory review.
A study of over 83,000 women found that initiating hormone therapy after age 65 significantly increases risks for cancer and cerebrovascular events, reinforcing current guidelines that discourage starting systemic hormone therapy after age 60.
Scientists at Cincinnati Children's have identified a molecular pathway responsible for immune checkpoint inhibitor-induced myocarditis and demonstrated that blocking TNF signaling can prevent this fatal complication without compromising anti-tumor efficacy.
Zai Lab announced an update on its Phase 1b/2 clinical study of ZL-1310, an experimental drug designed to treat advanced solid tumors with limited treatment options.
New antibody-based approaches demonstrate clinical benefits across multiple cancer types, including improved survival in triple-negative breast cancer, enhanced tumor detection via PET imaging, and activity in relapsed mantle cell lymphoma.
Analysis shows around a third of 54 drugs on TrumpRx.gov are cheaper in the UK, while the platform offers significant savings primarily for obesity and fertility drugs not typically covered by insurance.
Syndax Pharmaceuticals announced a collaboration to expand global access to Revuforj while reporting strong commercial performance for its two marketed products, with Revuforj generating $125 million and Niktimvo $152 million in the first 11 months of sales.
Colorectal cancer rates are rising 3% annually in adults under 50, prompting expanded screening efforts and new treatment approaches. Recent research shows promise in combination immunotherapy and vaccine strategies for advanced disease.
Multiple people were arrested following a city-wide narcotics enforcement operation in Hartford, Connecticut. Police seized over 1,000 sleeves of fentanyl, crack cocaine, a firearm, and more than $8,000 in cash.
Diakonos Oncology's Phase 2 glioblastoma trial of DOC1021 continues after independent safety review found no concerns. The company will present clinical data on the dendritic cell therapy at AACR and AAN conferences in April 2026.
New research shows home-based exercise reduces cognitive impairment during chemotherapy, while cardio-oncology programs monitor and minimize heart complications from cancer treatments that pose cardiovascular risks to survivors.
A longitudinal study of 460,000 teenagers found that adolescent cannabis use increases the risk of developing bipolar and psychotic disorders by twofold, as well as raising risks for depression and anxiety.
Research communities in the US and UK face funding disruptions as governments demand greater alignment with national priorities. UKRI has paused grant programs while early-career researchers advocate for increased NIH funding.
Researchers have developed advanced platforms to study human neural networks, including 3D bioelectronics for brain organoids and scalable 2D neuron networks that reveal brain-like rhythms and drug responses.
